These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17620865)

  • 1. Lipid metabolism: peroxisome proliferator-activated receptors.
    van Heyningen C
    Curr Opin Lipidol; 2007 Aug; 18(4):470-2. PubMed ID: 17620865
    [No Abstract]   [Full Text] [Related]  

  • 2. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid metabolism and metabolic disease: defining new targets.
    Cohn JS
    Curr Opin Lipidol; 2007 Jun; 18(3):237-9. PubMed ID: 17495594
    [No Abstract]   [Full Text] [Related]  

  • 4. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias.
    Yong EL; Li J; Liu MH
    Curr Opin Lipidol; 2008 Apr; 19(2):106-12. PubMed ID: 18388689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
    Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
    Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bibliography. Current world literature. Nutrition and metabolism.
    Curr Opin Lipidol; 2009 Feb; 20(1):63-72. PubMed ID: 19106709
    [No Abstract]   [Full Text] [Related]  

  • 7. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    J Nutrigenet Nutrigenomics; 2008; 1(3):126-35. PubMed ID: 19776622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors.
    Tsuji K; Satoh S; Mitsutake S; Murakami I; Park JJ; Li Q; Chang YT; Chung SK; Igarashi Y
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1643-6. PubMed ID: 19237283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis; cell biology and lipoproteins: lipid metabolism, eicosanoids, peroxisome proliferator activated receptors and the atherogenic process.
    Davidson J; Rotondo D
    Curr Opin Lipidol; 2006 Aug; 17(4):489-91. PubMed ID: 16832175
    [No Abstract]   [Full Text] [Related]  

  • 11. Nuclear hormone receptors and intestinal inflammation.
    Wu GD
    Gastroenterology; 2007 Oct; 133(4):1068. PubMed ID: 17919480
    [No Abstract]   [Full Text] [Related]  

  • 12. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptors: new players in the field of reproduction.
    Toth B; Hornung D; Scholz C; Djalali S; Friese K; Jeschke U
    Am J Reprod Immunol; 2007 Sep; 58(3):289-310. PubMed ID: 17681045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peroxisome proliferator-activated receptor in liver diseases].
    Zhao CY; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):382-4. PubMed ID: 12837233
    [No Abstract]   [Full Text] [Related]  

  • 15. [PPAR receptors at the crossroads of obesity, diabetes and cardiovascular diseases].
    Gilde A; Fruchart JC; Staels B
    Journ Annu Diabetol Hotel Dieu; 2007; ():21-38. PubMed ID: 18610756
    [No Abstract]   [Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC; Popeijus HE
    Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in research of molecular mechanism in alcoholic fatty liver disease].
    Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):878-80. PubMed ID: 17125628
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
    Bionaz M; Baumrucker CR; Shirk E; Vanden Heuvel JP; Block E; Varga GA
    J Dairy Sci; 2008 Jul; 91(7):2808-13. PubMed ID: 18565938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
    J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.